All In Biotech

Drug Trial Radar · NCT07807644

A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy

A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, 2-Part Phase 2 Trial to Investigate the Efficacy and Safety of GRT7040 in Adult Participants With Acute Pain Following Bunionectomy

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
First posted
Sep 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 clinical trial of GRT7040, currently being developed for the treatment of moderate-to-severe acute pain. The primary purpose of this trial is to assess efficacy and safety of GRT7040 compared with placebo in adult participants with acute pain following bunionectomy. The trial will compare three different doses of GRT7040 given from Day 1 until Day 3 (eg, 48 h after the first investigational medicinal product \[IMP\] administration) of GRT7040 or placebo.

Conditions

  • Acute Pain
  • Bunionectomy

Interventions

  • GRT7040Drug

    The trial will compare three different doses of GRT7040 (Low, Medium \[Mid\] and High doses)

  • Hydrocodone bitartrate/ acetaminophen (HB/APAP)Drug

    Reference drug

  • Placebo (matched to HB/APAP)Drug

    Dummy treatment

  • Placebo (matched to GRT7040)Drug

    Dummy treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-Weighted Sum of Pain Intensity Difference From 0 to 48 Hours (SPID48)Time frame: Baseline to 48 hours after first dose of IMP

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.